Scott Randal W.
SEC Form 4 insider trading activity
Scott Randal W. has filed 3 SEC Form 4 filings (12 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: May 19, 2026.
On the most recent filing, Scott Randal W. is listed as Director at BridgeBio Pharma, Inc. Inside the rolling window, Scott Randal W. reported no open-market purchases and 3 open-market sales totaling $2.1M in BBIO. The largest disclosed transaction in the window is a sale of 10,000 BBIO shares on Feb 17, 2026, worth $755K.
Companies traded
Other insiders at BBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.1M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Scott Randal W. made?
Scott Randal W. has filed 3 SEC Form 4 filings (12 transaction rows) across 1 company since 2025.
Which companies does Scott Randal W. trade?
Scott Randal W. has filed SEC Form 4 disclosures for 1 company, including BBIO.
When was Scott Randal W.'s most recent SEC Form 4 filing?
Scott Randal W.'s most recent SEC Form 4 filing on Tracefour is dated May 19, 2026.
What is Scott Randal W.'s total buy and sell value in the current window?
Inside the rolling retention window, Scott Randal W. bought $0 and sold $2.1M based on SEC Form 4 filings.
What was Scott Randal W.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,000 BBIO shares on 2026-02-17, worth $755K, per SEC Form 4 filings.